Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment

Nature Clinical Practice Oncology volume 5, pages 250–251 (2008)Cite this article

boxed-textFuchs CS et al. (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 25: 4779–4786

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Douillard JY et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041–1047

    Article  CAS  Google Scholar 

  2. de Gramont A et al. (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808–815

    Article  CAS  Google Scholar 

  3. Colucci G et al. (2005) Phase III randomized trial of FOLFIRI versus FOLFOX 4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23: 4866–4875

    Article  CAS  Google Scholar 

  4. Rea DW et al. (2005) A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16: 1123–1132

    Article  CAS  Google Scholar 

  5. Koopman M et al. (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370: 135–142

    Article  CAS  Google Scholar 

  6. Midgley RM and Kerr DJ (2008) Capecitabine: have we got the dose right? Nat Clin Pract Oncol (in press)

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Clinical Pharmacology, University of Oxford, Old Road Campus Research Building, Old Road Campus off Roosevelt Drive, Headington, Oxford OX3 7DQ, UK david.kerr@clinicalpharmacology.oxford.ac.uk

Authors and Affiliations

  1. DJ Kerr is Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics at the Department of Clinical Pharmacology, University of Oxford, Oxford, UK.,

    David J Kerr

Authors
  1. David J Kerr
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

D Kerr is a speaker and receives grant/research support from Roche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kerr, D. Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment. Nat Rev Clin Oncol 5, 250–251 (2008). https://doi.org/10.1038/ncponc1108

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1108

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing